MON

Monsanto Co

Industrial/Transportation, Event Driven/Special Sit


Presented:06/09/2016
Price:$109.99
Cap:$48.58B
Current Price:$10.07
Cap:$0.31B

Presented

Date06/09/2016
Price$109.99
Market Cap$48.58B
Ent Value$47.71B
P/E Ratio34.59x
Book Value$9.51
Div Yield0.02%
Shares O/S441.70M
Ave Daily Vol4,379,394
Short Int1.76%

Current

Price$10.07
Market Cap$0.31B
Monsanto Co. engages in the distribution of agricultural products to farmers. The company operates its business through the following business segments: Seeds & Genomics and Agricultural Productivity. The Seeds & Genomics segment produces seed brands, including DEKALB, Asgrow, Deltapine, Seminis, and De Ruiter and develops biotechnology traits that assist farmers in controlling insects and weeds. The Agricultural Productivity segment manufactures Roundup and Harness brand herbicides and other herbicides. It also provides other seed companies with genetic material and biotechnology traits for their seed brands. Monsanto was founded by John F. Queeny in 1901 and is headquartered in St. Louis, MO.

Publicly traded companies mentioned herein: BASF SE (BAS GR), Bayer AG (BAY GR), Dow Chemical Co (DOW), EI du Pont de Nemours & Co (DD), Monsanto Company (MON), Syngenta AG (SYT)

Highlights

Shares of Monsanto (MON) have traded between $105 and $113 since Bayer made the all-cash, $122 per share ($62 billion) offer to buy the company. The presenter is long the stock, and sees ~$109 - $110 as a good entry point. He noted that Bayer’s offer is just slightly above MON’s 52-week high of $115.45, but appears to be timely given the recent pressure on commodity and agriculture stocks as underlying commodities faced weakness (most notably, corn and soybeans have been under pressure over the last 6 - 9 months). He believes MON’s response was a surprise to the market, as their willingness to undertake a conversation/ negotiation was conveyed in a relatively “friendly” press release in the context of an unsolicited proposal. If $122 is the starting point for the negotiation the risk/ reward is favorable, and if Bayer is as committed to getting a deal done as it seems the final offer could fall in the $135 - $140 price range.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.